Morphosys has a new Chief Financial Officer. Sung Lee has been appointed to the post. He will take office on February 2nd. Lee succeeds Jens Holstein, who left the company in December.
Marc Cluzel, Chairman of the Board of Directors of MorphoSys, praised the new CFO: “Sung Lee brings many years of experience to the Board of Directors and has an excellent track record of expanding companies and leading investor relations and finance in the US and Europe.” CEO Jean-Paul Kress adds: “We are convinced that Sung Lee, with his future-oriented way of thinking, will provide decisive impetus for the implementation of our ambitious growth strategy and the accelerated development of our pipeline in the interests of patients.”
Lee comes from Sangamo Therapeutics, where he was also the Chief Financial Officer. Prior to that, he worked for Gilead Sciences and Tax Advisory at PriceWaterhouseCoopers. He studied in California.